StockData
Sutro Biopharma, Inc. logo

Sutro Biopharma, Inc. (STRO) stock

STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$8.50−0.42 (-4.71%)

Close on Nov 18, 2026Market cap $140.94MP/E –Yield –

Sutro Biopharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Sutro Biopharma's free cash flow for the twelve months ending Sep 30, 2019 was -$60.03M, down 585.6% year over year. For fiscal 2018 it was $11.13M.

Annual free cash flow

PeriodPeriod endValueChange
FY2018Dec 31, 2018$11.13M–
FY2017Dec 31, 2017-$40.39M–
FY2016Dec 31, 2016-$17.55M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2020Mar 31, 2020-$19.50M–
Q3 FY2019Sep 30, 2019-$16.79M-135.6%
Q2 FY2019Jun 30, 2019-$16.09M–
Q1 FY2019Mar 31, 2019-$20.42M–
Q4 FY2018Dec 31, 2018-$6.73M–
Q3 FY2018Sep 30, 2018$47.21M–
Q2 FY2018Jun 30, 2018-$13.98M–
Q1 FY2018Mar 31, 2018-$15.37M–
Q4 FY2017Dec 31, 2017-$5.50M–

More Sutro Biopharma figures

See a number that looks wrong?